Estudios Epidemiológicos
- VAC-CaP
- Thoracic Tumor Registry (TTR)
- OSIREX
- SOLID
- GRAVID
VAC-CaP
(GECP 21/01)
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer.
Thoracic Tumor Registry (TTR)
(GECP 16/01)
Thoracic Tumours Register
NCT02941458
Substudy: TTR-ATLAS
A Spanish Nationwide Biomarker NGS Testing Platform For Lung Cancer.
Substudy: TTR-ATLAS-RADON
Radon Measurement In Homes Of Lung Cancer Patients.
OSIREX
(GECP 18/01)
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain.
SOLID
(GECP 20/04)
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection (SOLID).
NCT04407143
Substudy: SOLID I
The scope is the identification of acquired immunity (IgG) in patients with lung cancer, whether or not they have presented symptoms of having suffered from COVID19. In addition, the description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection will be carried out.
Substudy: SOLID II
The scope is the confirmation of the presence of antibodies (IgG) in patients who tested positive in Phase I of the study a few weeks after the first diagnosis made through the SOLID study.
Substudy: SOLID III
The scope is the confirmation of the presence of antibodies (IgG) in patients with lung cancer who have been vaccinated with any of the available and authorized vaccines for SARS-COV2 and 6 months after said administration.
GRAVID
(GECP 20/02)
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease.